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Abstract
OBJECTIVES: Cardiac surgery-associated acute kidney injury (AKI) is a well-known factor influencing patients’ long-term morbidity and
mortality. Several prediction models of AKI requiring dialysis (AKI-D) have been developed. Only a few direct comparisons of these
models have been done. Recently, a new, more uniform and objective definition of AKI has been proposed [Kidney Disease: Improve
Global Outcomes (KDIGO)-AKI]. The performance of these prediction models has not yet been tested.
METHODS: Preoperative demographic and clinical characteristics of 1056 consecutive adult patients undergoing cardiac surgery were col-
lected retrospectively for the period 2012–2014. Multivariable logistic regression analysis was used to determine the independent predic-
tors of AKI-D and the KDIGO-AKI stages. Risk scores of five prediction models were calculated using corresponding subgroups of patients.
The discrimination of these models was calculated by the c-statistics (area under curve, AUC) and the calibration was evaluated for the
model with the highest AUC by calibration plots.
RESULTS: The incidence of AKI-D was 3.5% and for KDIGO-AKI 23% (17.3% for Stage 1, 2.1% for Stage 2 and 3.6% for Stage 3). Older age,
atrial fibrillation, NYHA class III or IV heart failure, previous cardiac surgery, higher preoperative serum creatinine and endocarditis were
independently associated with the development of AKI-D. For KDIGO-AKI, higher body mass index, older age, female gender, chronic
obstructive pulmonary disease, previous cardiac surgery, atrial fibrillation, NYHA class III or IV heart failure, higher preoperative serum cre-
atinine and the use of cardiopulmonary bypass were independent predictors. The model by Thakar et al. showed the best performance in
the prediction of AKI-D (AUC 0.837; 95% CI = 0.810–0.862) and also in the prediction of KDIGO-AKI stage 1 and higher (AUC = 0.731; 95%
CI = 0.639–0.761), KDIGO-AKI stage 2 and higher (AUC = 0.811; 95% CI = 0.783–0.838) and for KDIGO-AKI stage 3 (AUC = 0.842; 95%
CI = 0.816–0.867).
CONCLUSIONS: The performance of known prediction models for AKI-D was found reasonably well in the prediction of KDIGO-AKI, with
the model by Thakar having the highest predictive value in the discrimination of patients with risk for all KDIGO-AKI stages.
Keywords: Acute kidney injury • Cardiac surgery • Renal replacement therapy • Dialysis • Risk factors • Kidney Disease: Improve Global
Outcomes
INTRODUCTION
Acute kidney injury (AKI), developing after cardiac surgery, is an
important factor determining patients’ outcome. It is associated
with an increased morbidity and mortality, as well as with pro-
longed duration and costs of hospitalization [1–3]. Therefore, it is
important to identify risk factors for postoperative AKI, and to
prevent those adverse outcomes. Several predictive models of
cardiac surgery-associated acute kidney injury (CS-AKI) have been
developed [4–14]. The models of Chertow et al. [4], Fortescue et al.
[5], Thakar et al. [6], Mehta et al. [7] and Wijeysundera et al. [8] have
been externally validated several times, showing reasonable dis-
crimination of patients with the risk for AKI [15–20]. The reported
incidence of CS-AKI is variable, and depends on definition of AKI
as well as on inclusion and exclusion criteria.
Reported incidence of CS-AKI defined with the need for renal
replacement therapy (RRT; dialysis and AKI-D) ranges from 0.4 to
10.9%, with an average between 1 and 2% [4–8, 14, 15, 18, 20].
Some authors found that AKI with even small increases in serum
creatinine was also associated with an increased risk of morbidity
and mortality [1, 3, 21]. When defined with smaller reduction in
renal function, reported incidence of CS-AKI ranges from 2.7 to
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39% [9–12, 14, 22]. Recently, the ‘Kidney Disease: Improve Global
Outcomes’ (KDIGO) AKI study group has suggested a modified
definition of AKI, levelling the differences between earlier AKI
definitions and enabling better reproducibility and comparison
between different prediction models [23].
The aim of our study was to identify potential preoperative risk
factors for CS-AKI defined as AKI-D and AKI according to KDIGO
criteria (KDIGO-AKI) in our University Hospital. Furthermore, we
evaluated the performance of several known models [5–9] in the
prediction of KDIGO-AKI in our patient cohort.
MATERIALS ANDMETHODS
We conducted a retrospective cohort study, which included all
consecutive patients aged >18 years undergoing cardiac surgery at
the Department of Cardiac and Transplant Surgery of University
Hospital Dubrava in Zagreb, Croatia, between 1 January 2012 and
31 December 2014. Exclusion criteria were preoperative RRT, in-
cluding dialysis and renal transplant recipients, death within 24 h
after surgery, infrequent surgical procedures (heart transplant-
ation, ventricular assist device(s) implantation, pericardiectomy
and isolated heart tumour resection) and preoperative use of
extracorporeal membrane oxygenation.
Demographic characteristics and potential preoperative predic-
tors of AKI were extracted from the cardiac surgery database, hos-
pital database and medical records. The variables extracted were
those included in the original studied models [5–9]: age, gender,
weight, height, smoking habits, history and treatment of diabetes,
chronic obstructive pulmonary disease (COPD) or asthma, hyper-
tension, peripheral arterial vascular disease, previous cardiac
surgery, recent myocardial infarction (within 3 weeks before
surgery), atrial fibrillation (AF), systolic blood pressure, preopera-
tive renal function parameters, white blood cell count (the last
preoperative value), left ventricular ejection fraction (LVEF; mea-
sured preoperatively with transthoracic echocardiography), use of
intra-aortic balloon pump before surgery, congestive heart failure
(CHF, defined with NYHA class III or IV), cardiogenic shock, endo-
carditis, operative status (elective or non-elective, i.e. emergent or
urgent), use of cardiopulmonary bypass (CPB) and types of
surgery: coronary artery bypass grafting (CABG), aortic valve (AV)
surgery, mitral valve (MV) surgery, other valves surgery and com-
binations of former surgery.
Preoperative renal function was defined by serum creatinine
(using the last preoperative value measured within 3 days before
surgery) and by estimated glomerular filtration rate (EGFR), calcu-
lated with Cockroft–Gault, MDRD and CKDEPI equations [24].
If there were more than one cardiac surgery procedures per-
formed during the same hospitalization, only the data before the
first surgery were considered.
To avoid any interpretation bias, especially those regarding pre-
dictors inclining subjective interpretation, like CHF, the evaluation
of all patients was done by one physician.
The primary outcome was the development of AKI, defined
with the initiation of dialysis in the postoperative course, until the
discharge of the patient (AKI-D). The dialysis was started at the
discretion of the attending physician based on the standard cri-
teria such as uraemia, acidosis, hyperkalaemia or severe fluid
overload. The secondary outcome was AKI defined and staged
with KDIGO criteria (KDIGO-AKI) into stages 1–3 (no AKI develop-
ment was marked as KDIGO-AKI stage 0), using the highest post-
operative serum creatinine within the time frames as in the KDIGO
definitions [23]. KDIGO-AKI stage 1 was defined with an increase of
serum creatinine by 1.5–1.9 times baseline or by ≥26.5 μmol/l from
baseline. KDIGO-AKI stage 2 was defined with an increase of serum
creatinine by 2.0–2.9 times baseline. KDIGO-AKI stage 3 was defined
with an increase of serum creatinine by ≥3.0 times baseline or with
serum creatinine of ≥353.6 μmol/l or with the initiation of RRT. Owe
to incomplete data on urine output, only data on serum creatinine
were used to determine the stage of KDIGO-AKI.
In the performance evaluation of different models, the predic-
tion scores were calculated as in the original studies [5–9]. Patients
who did not meet the original inclusion criteria for a certain
model were excluded from the analysis of that specific model
(Fig. 1 and Supplementary Table 1).
Statistical analysis
Continuous variables are expressed as mean ± standard deviation
or median with an interquartile range as appropriate after check-
ing for normality. The categorical variables are reported as fre-
quency number and percentage. Univariable analysis of predictors
for dichotomous outcomes was done by Student’s t-test or Mann–
Whitney U-test for continuous variables and by the χ2 test or
Fischer’s exact test for categorical variables. In the univariable ana-
lysis of predictors for KDIGO-AKI stages 1–3, ANOVA (with the
post hoc Bonferroni method) or Kruskal–Wallis test (post hoc
Mann–Whitney U-test) was used as appropriate to compare con-
tinuous variables and χ2 test or Fisher’s exact test for comparison
of categorical variables. Multivariable analysis of predictors was
Figure 1: Patient cohort and subgroup selection for the analysis of the different
models.
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done by logistic regression with a stepwise method using signifi-
cant predictors found in the univariable analysis.
Evaluation of the performance of different prediction models
of CS-AKI was done by discrimination and calibration analysis.
Discrimination analysis of each predictive model score was made
by calculating the c-statistics, i.e. area under curve (AUC) for each
model. Comparison of dependent or independent AUC for differ-
ent outcomes within the same model or for the same outcome
between different models was done by the DeLong method [25].
The model with the greatest AUC was then used for calibration
analysis in our patient cohort by creating calibration plots and
graphic comparison of observed and expected (as in the original
study) outcome rates for the same risk category.
A two-sided P-value of <0.05 was considered as statistically sig-
nificant. The data were analysed using SPSS version 17.0 and
MedCalc version 11.4.2.0.
RESULTS
The study population consisted of 1147 patients, of which 91 were
excluded, so our global cohort included 1056 Caucasian patients
(Fig. 1). Baseline demographic and clinical characteristics of the
global patient cohort and their association with AKI-D are given in
Table 1. AKI-D was found in 37 patients (3.5%). In univariable ana-
lysis, older age, diabetes, previous cardiac surgery, AF, CHF (NYHA
class III or IV), higher serum creatinine (lower EGFR), endocarditis
and type of surgery were associated with AKI-D (Table 1).
KDIGO-AKI developed in 244 patients (23.1%), of which 183
(17.3%) were KDIGO-AKI stage 1, 23 (2.2%) were stage 2 and 38
(3.6%) were KDIGO-AKI stage 3. Distribution of baseline demo-
graphic and clinical characteristics of patients and their association
with KDIGO-AKI stages are given in Table 2. Older age, female
gender, higher body mass index (BMI), diabetes, COPD, previous
Table 1: Baseline patient characteristics and the association with AKI-D
Global cohort (n = 1056) No AKI-D (n = 1019) AKI-D (n = 37) P-value
Age (years) 64 (57–71) 64 (57–71) 70 (64–74) 0.001a
Male sex (%) 766 (72.5) 741 (72.7) 25 (67.6) n.s.
Weight (kg) 82.24 (13.98) 82.10 (13.73) 85.95 (19.55) n.s.
Height (cm) 171.14 (9.08) 171.17 (9.12) 170.35 (7.80) n.s.
BMI (kg/m2) 28.05 (4.07) 28.00 (3.98) 29.51 (5.79) n.s.
BSA (m2) 1.94 (0.19) 1.94 (0.19) 1.97 (0.23) n.s.
Smoking (%) 163 (15.4) 160 (15.7) 3 (8.1) n.s.
Diabetes 0.027b
On OHG (%) 197 (18.7) 191 (18.7) 6 (16.2)
On insulin (%) 107 (10.1) 98 (9.6) 9 (24.3) 0.009b
COPD (%) 95 (9.0) 89 (8.7) 6 (16.2) n.s.
PVD (%) 63 (6.0) 61 (6.0) 2 (5.4) n.s.
Previous cardiac surgery (%) 38 (3.6) 32 (3.1) 6 (16.2) 0.001b
Hypertension (%) 818 (77.5) 788 (77.3) 30 (81.1) n.s.
SBP (mmHg) 129.01 (15.84) 129.16 (15.66) 125.0 (20.0) n.s.
Atrial fibrillation (%) 136 (12.9) 119 (11.7) 17 (45.9) <0.0001b
Recent MI (<3 weeks) (%) 83 (7.9) 82 (8.0) 1 (2.7) n.s.
CHF or NYHA III–IV (%) 153 (14.5) 134 (13.2) 19 (51.4) <0.0001b
Cardiogenic shock (%) 2 (0.2) 2 (0.2) 0 (0.0) n.s.
LVEF (%) 54.66 (11.12) 54.83 (11.01) 49.76 (13.04) 0.025c
White blood cell count (×1012/l) 7.4 (6.1–9.0) 7.4 (6.1–8.9) 8.0 (6.3–9.2) n.s.
Serum creatinine (μmol/l) 97 (86–112) 97 (86–111) 122 (92–185) <0.0001a
EGFR—CG (ml/min) 77.00 (25.07) 77.74 (24.72) 56.56 (26.39) <0.0001c
EGFR—CKDEPI (ml/min) 76.35 (19.29) 77.20 (18.58) 53.0 (23.54) <0.0001c
Preoperative IABP (%) 8 (0.8) 7 (0.7) 1 (2.7) n.s.
Emergency surgery (%) 215 (20.4) 203 (19.9) 12 (32.4) n.s.
Endocarditis (%) 51 (4.8) 43 (4.2) 8 (21.6) <0.0001b
Cardiopulmonary bypass (%) 824 (78.03) 791 (77.6) 33 (88.2) n.s.
Surgery type (%) 0.002b
CABG only 531 (50.3) 521 (51.1) 10 (27.0) 0.003b
AV surgery only 268 (25.4) 260 (25.5) 8 (21.7)
MV surgery only 101 (9.6) 91 (8.9) 10 (27.0)
CABG + AV surgery 74 (7.0) 70 (6.9) 4 (10.8)
CABG +MV surgery 32 (3.0) 31 (3.0) 1 (2.7)
CABG + AV +MV surgery 4 (0.4) 4 (0.4) 0 (0.0)
AV +MV surgery 28 (2.6) 24 (2.4) 4 (10.8)
Other 18 (1.7) 18 (1.8) 0 (0.0)
Continuous variables are presented as mean (SD) or median (IQ range) where appropriate, and categorical variables are presented as number (%).
AKI: acute kidney injury; AKI-D: acute kidney injury requiring dialysis; AV: aortic valve; BMI: body mass index; BSA: body surface area; CABG: coronary artery
bypass grafting; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; CPB: cardiopulmonary bypass; EGFR: estimated glomerular
filtration rate (CG—according to Cockroft–Gault equation; CKDEPI: according to the CKDEPI equation); IABP: intra-aortic balloon pump; LVEF: left ventricular
ejection fraction; MI: myocardial infarction; MV: mitral valve; n.s.: not significant; NYHA: class according to New York Heart Association; OHG: oral
hypoglycaemic drugs; PVD: peripheral vascular disease; SBP: systolic blood pressure.
aMann–Whitney U-test.
bχ2 or Fisher’s exact test.
cStudent’s t-test.
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Table 2: Baseline patient characteristics and the association with KDIGO-AKI stages
Global cohort
(n = 1056)
KDIGO-AKI 0
(n = 812)
KDIGO-AKI 1
(n = 183)
KDIGO-AKI 2
(n = 23)
KDIGO-AKI 3
(n = 38)
P-value
Age (years) 64 (57–71) 63 (56–70) 69 (60–73) 70 (66–76) 69 (64–74) <0.001a
Post hoc AKI-0 versus AKI-1 <0.001
Post hoc AKI-0 versus AKI-2 <0.001
Post hoc AKI-0 versus AKI-3 <0.001
Male sex (%) 766 (72.5) 605 (74.5) 123 (67.2) 12 (52.2) 26 (68.4) 0.026b
Weight (kg) 82.24 (13.98) 81.68 (13.73) 83.69 (13.79) 84.57 (12.96) 85.71 (19.34) n.s.
Height (cm) 171.14 (9.08) 171.49 (8.88) 169.99 (9.99) 169.0 (9.62) 170.55 (7.79) n.s.
BMI (kg/m2) 28.05 (4.07) 27.73 (3.87) 28.98 (4.27) 29.66 (4.01) 29.37 (5.77) <0.001
Post hoc AKI-0 versus AKI-1 <0.001
BSA (m2) 1.94 (0.19) 1.94 (0.19) 1.95 (0.19) 1.95 (0.18) 1.97 (0.22) n.s.
Smoking (%) 163 (15.4) 137 (16.9) 21 (11.5) 2 (8.7) 3 (7.9) n.s.
Diabetes 0.008b
On OHG (%) 197 (18.7) 150 (18.5) 33 (18.0) 8 (34.8) 6 (15.8)
On insulin (%) 107 (10.1) 69 (8.5) 27 (14.8) 2 (8.7) 9 (23.7)
COPD (%) 95 (9.0) 62 (7.6) 25 (13.7) 2 (8.7) 6 (15.8) 0.025b
PVD (%) 63 (6.0) 43 (5.3) 16 (8.7) 2 (8.7) 2 (5.3) n.s.
Previous cardiac surgery (%) 38 (3.6) 22 (2.7) 8 (4.4) 2 (8.7) 6 (15.8) 0.001b
Hypertension (%) 818 (77.5) 624 (76.8) 145 (79.2) 18 (78.3) 31 (81.6) n.s.
SBP (mmHg) 129.01 (15.84) 129.14 (15.25) 129.61 (16.59) 125.43 (21.53) 125.66 (20.14) n.s.
Atrial fibrillation (%) 136 (12.9) 79 (9.7) 31 (16.9) 9 (39.1) 17 (44.7) <0.001b
Recent MI (<3 weeks) (%) 83 (7.9) 59 (7.3) 20 (10.9) 3 (13.0) 1 (2.6) n.s.
CHF or NYHA III–IV (%) 153 (14.5) 79 (9.7) 48 (26.2) 7 (30.4) 19 (50.0) <0.001b
Cardiogenic shock (%) 2 (0.2) 0 (0.0) 2 (1.1) 0 (0.0) 0 (0.0) n.s.
LVEF (%) 54.66 (11.12) 55.44 (10.57) 52.57 (12.10) 50.65 (14.02) 50.29 (13.27) <0.001c
Post hoc AKI-0 versus AKI-1 0.009
Post hoc AKI-0 versus AKI-3 0.03
White blood cell count
(×1012/l)
7.4 (6.1–9.0) 7.4 (6.1–8.85) 7.6 (6.2–9.4) 6.9 (5.3–9.7) 8.0 (6.3–9.2) n.s.
Serum creatinine (μmol/l) 97 (86–112) 95 (85–107) 104 (91–125) 103 (83–116) 126.5 (92–189) <0.001a
Post hoc AKI-0 versus AKI-1 <0.001
Post hoc AKI-0 versus AKI-3 <0.001
Post hoc AKI-1 versus AKI-3 0.003
Post hoc AKI-2 versus AKI-3 0.002
EGFR—CG (ml/min) 77.00 (25.07) 79.92 (24.3) 69.52 (25.27) 68.58 (16.46) 55.71 (26.55) <0.001c
Post hoc AKI-0 versus AKI-1 <0.001
Post hoc AKI-0 versus AKI-3 <0.001
Post hoc AKI-1 versus AKI-3 0.009
EGFR—CKDEPI (ml/min) 76.35 (19.29) 79.68 (17.37) 67.64 (20.31) 67.93 (14.93) 52.15 (23.81) <0.001c
Post hoc AKI-0 versus AKI-1 <0.001
Post hoc AKI-0 versus AKI-2 0.013
Post hoc AKI-0 versus AKI-3 <0.001
Post hoc AKI-1 versus AKI-3 <0.001
Post hoc AKI-2 versus AKI-3 0.006
Preoperative IABP (%) 8 (0.8) 4 (0.5) 3 (1.6) 0 (0.0) 1 (2.6) n.s.
Emergency surgery (%) 215 (20.4) 151 (18.6) 45 (24.6) 7 (30.4) 12 (31.6) 0.041b
Endocarditis (%) 51 (4.8) 33 (4.1) 8 (4.4) 2 (8.7) 8 (21.1) 0.001b
Cardiopulmonary bypass (%) 824 (78.03) 609 (75.0) 163 (89.1) 18 (78.3) 34 (89.5) <0.001b
Surgery type (%) <0.0001b
CABG only 531 (50.3) 457 (56.3) 59 (32.2) 5 (21.8) 10 (26.3)
AV surgery only 268 (25.4) 196 (24.1) 57 (31.1) 7 (30.4) 8 (21.1)
MV surgery only 101 (9.6) 67 (8.3) 21 (11.5) 3 (13.0) 10 (26.3)
CABG + AV surgery 74 (7.0) 43 (5.3) 21 (11.5) 5 (21.8) 5 (13.2)
CABG +MV surgery 32 (3.0) 15 (1.8) 13 (7.2) 3 (13.0) 1 (2.6)
CABG + AV +MV surgery 4 (0.4) 3 (0.4) 1 (0.5) 0 (0.0) 0 (0.0)
AV +MV surgery 28 (2.6) 17 (2.1) 7 (3.8) 0 (0.0) 4 (10.5)
Other 18 (1.7) 14 (1.7) 4 (2.2) 0 (0.0) 0 (0.0)
Continuous variables are presented as mean (SD) or median (IQ range) where appropriate, and categorical variables are presented as number (%).
AKI: acute kidney injury; AV: aortic valve; BMI: body mass index; BSA: body surface area; CABG: coronary artery bypass grafting; CHF: congestive heart failure;
COPD: chronic obstructive pulmonary disease; EGFR: estimated glomerular filtration rate (CG—according to the Cockroft–Gault equation; CKDEPI: according
to the CKDEPI equation); LVEF: left ventricular ejection fraction; MI: myocardial infarction; MV: mitral valve; n.s.: non-significant (P ≥ 0.05); NYHA: class
according to New York Heart Association; OHG: oral hypoglycaemic drugs; PVD: peripheral vascular disease; SBP: systolic blood pressure; KDIGO-AKI stages
1–3 (stage 0 = no AKI): according to Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group [23].
aKruskal–Wallis test and post hocMann–Whitney U-test.
bχ2 or Fisher’s exact test.
cANOVA and post hoc Bonferroni.
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cardiac surgery, AF, CHF (NYHA class III or IV), lower LVEF, higher
preoperative serum creatinine (lower EGFR), emergency surgery,
endocarditis, type of surgery (other versus isolated CABG) and use
of CPB were associated with the development of KDIGO-AKI
(Table 2). Bivariable associations of patient characteristics with the
KDIGO-AKI stages 1 and higher are given in Supplementary Table
2, with KDIGO-AKI stages 2 and higher in Supplementary Table 3
and with KDIGO-AKI stage 3 in Supplementary Table 4.
Multivariable logistic regression showed older age, AF, CHF
(NYHA class III or IV), previous cardiac surgery, higher serum
creatinine and endocarditis independently associated with the
development of AKI-D (Table 3). Also in Table 3, the results of multi-
variable logistic regression analysis for the development of different
stages of KDIGO-AKI are given. For KDIGO-AKI stage 1 and higher
(versus no AKI), greater BMI, older age, female gender, COPD, previ-
ous cardiac surgery, AF, CHF (NYHA class III or IV), higher serum cre-
atinine and the use of CPB were independent predictors.
Performance evaluation of different prediction
models (scores)
The tested models were not applicable to all global cohort
patients due to inclusion and exclusion criteria of the tested
models (Fig. 1 and Supplementary Table 1). The discrimination of
each model (risk score), measured with AUC, for occurrence of
AKI-D and for the each stage of KDIGO-AKI is given in Table 4.
Reliable calculation of AUC was not possible for the AKI-D and
KDIGO-AKI stages 2 and 3 using the Brown et al. model [9], due to
a small number of events. For the original outcome of the Brown
et al. model (EGFR <30 ml/min) [9], the AUC was also not calcu-
lated due to the same reason.
The comparison of different models shows that the highest AUC
for all outcomes and stages of CS-AKI has the model of Thakar
et al. [6]. Compared with the model of Wijeysundera et al. [8] (the
same patient subgroup), this was statistically significant for all out-
comes: for AKI-D versus no AKI-D (P = 0.0021), for KDIGO-AKI
stages 1 and higher versus KDIGO-AKI 0 (P = 0.0001), for KDIGO-
AKI stages 2 and higher versus KDIGO-AKI 0–1 (P = 0.0015) and
for KDIGO-AKI stage 3 versus KDIGO-AKI 0–2 (P = 0.0008). The
results also show that smaller AUC was found in all the models for
the lower stages of KDIGO-AKI (Table 4).
Analysis of calibration of the best performing model in the dis-
crimination for CS-AKI (the model of Thakar et al. [6]) is shown in
Fig. 2. Patient characteristics between the Thakar et al. [6] original
cohort and our subgroup for the model analysis are given in
Supplementary Table 5, and frequencies of AKI-D at different score
levels and risk categories are given in Supplementary Table 6.
Table 3: Predictors of AKI in multivariable logistic regression in the global cohort (n = 1056)
OR (95% CI) P-value AUC (95% CI)
For acute kidney injury—dialysis versus no dialysis
Age (years) 1.072 (1.023–1.124) 0.0035 0.896 (0.876–0.914)
Atrial fibrillation (yes versus no) 4.642 (2.015–10.698) 0.0003
CHF/NYHA class III or IV (yes versus no) 2.689 (1.189–6.078) 0.0175
Previous cardiac surgery (yes versus no) 5.323 (1.635–17.325) 0.0055
Serum creatinine (μmol/l) 1.022 (1.014–1.023) <0.0001
Endocarditis (yes versus no) 9.408 (2.702–32.764) 0.0004
For KDIGO-AKI stages 1–3 versus stage 0 (no AKI)
BMI (kg/m2) 1.105 (1.061–1.151) <0.0001 0.780 (0.753–0.804)
Age (years) 1.034 (1.016–1.053) 0.0002
Gender (female versus male) 1.572 (1.085–2.278) 0.0169
COPD (yes versus no) 1.757 (1.065–2.897) 0.0273
Previous cardiac surgery (yes versus no) 2.888 (1.313–6.355) 0.0084
Atrial fibrillation (yes versus no) 1.599 (1.033–2.475) 0.0352
CHF/NYHA class III or IV (yes versus no) 3.314 (2.195–5.004) <0.0001
Serum creatinine (μmol/l) 1.021 (1.015–1.027) <0.0001
CPB (yes versus no) 2.243 (1.407–3.577) 0.0007
For KDIGO-AKI stages 2–3 versus stages 0–1
BMI (kg/m2) 1.111 (1.037–1.189) 0.0026 0.872 (0.850–0.891)
Age (years) 1.086 (1.045–1.129) <0.0001
Previous cardiac surgery (yes versus no) 4.917 (1.725–14.016) 0.0029
Atrial fibrillation (yes versus no) 4.164 (2.182–7.946) <0.0001
CHF/NYHA class III or IV (yes versus no) 2.437 (1.252–4.741) 0.0087
Serum creatinine (μmol/l) 1.017 (1.010–1.023) <0.0001
Endocarditis (yes versus no) 9.693 (3.204–29.324) 0.0001
For KDIGO-AKI stage 3 versus stages 0–2
Age (years) 1.071 (1.022–1.122) 0.0043 0.897 (0.878–0.915)
Previous cardiac surgery (yes versus no) 5.533 (1.698–18.034) 0.0045
Atrial fibrillation (yes versus no) 4.411 (1.917–10.149) 0.0005
CHF/NYHA class III or IV (yes versus no) 2.521 (1.112–5.718) 0.0269
Serum creatinine (μmol/l) 1.024 (1.017–1.032) <0.0001
Endocarditis (yes versus no) 8.768 (2.491–30.855) 0.0007
Continuous variables are presented as mean (SD) or median (IQ range) where appropriate, and categorical variables are presented as number (%).
AKI: acute kidney injury; AUC: area under curve; BMI: body mass index; CI: confidence interval; CHF: congestive heart failure; COPD: chronic obstructive
pulmonary disease; CPB: cardiopulmonary bypass; NYHA: class according to New York Heart Association; KDIGO-AKI stages 1–3 (stage 0 = no AKI): according
to Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group [23].
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The calibration of the model was poor, as shown by calibration-
in-large analysis (Fig. 2). When applied to our patients, the model
of Thakar et al. [6] underestimated the risk of AKI-D except in the
lower risk categories (Fig. 2). The optimal cut-off value for the
Thakar model score in the prediction of AKI-D was 2 in our
patient cohort, with sensitivity of 90.91%, specificity of 65.23%,
positive-likelihood ratio 2.61 and negative-likelihood ratio of 0.14.
DISCUSSION
In this study, we aimed to explore risk factors for the development
of AKI after cardiac surgery, as well as to evaluate the performance
of well-known prediction models [5–9] in our population cohort.
Preoperative evaluation and identification of patients, who are
at greater risk for the development of AKI, could lead to more
optimal perioperative care and improve patients outcome. The
most often used prediction models of CS-AKI have been devel-
oped in the USA and Canada [5–9], and later validated in other
regions of the world, including European population cohorts as
well [15–20]. The definition of the primary outcome (AKI) in this
setting is the first big issue that needs to be addressed, because
different definitions of AKI make the comparison and validation of
studies difficult. Most authors defined AKI with the initiation of
RRT (dialysis) [5–9], but other definitions were also used [10–14].
To overcome the differences in the definition of AKI in general,
KDIGO-AKI criteria have been proposed recently [23]. We chose
AKI-D as the primary outcome, because the original, most often
utilized and tested prediction models, had the same outcome
[5–8, 15–20]. Also, we studied KDIGO-AKI as the secondary
outcome and the association of predictors with different stages of
KDIGO-AKI, as well as performance of known prediction models
regarding this outcome. There has been only one study evaluating
CS-AKI according to KDIGO-AKI criteria, by Machado et al., but
the primary goal of this study was to evaluate the prognostic sig-
nificance of KDIGO-AKI stages and not to explore the risk factors
for AKI [3]. In our study, we included all cardiac surgery patients
operated with and without CPB, with usual exclusion criteria as
mentioned before and in concordance with the majority of studies.
Table 4: Evaluation by discrimination (measured with AUC) of five risk scores for outcomes: AKI requiring dialysis and KDIGO-AKI
stages 1–3 in our patient cohort
AKI-dialysis
AUC (95% CI)
KDIGO-AKI 1–3
AUC (95% CI)
KDIGO-AKI 2–3
AUC (95% CI)
KDIGO-AKI 3
AUC (95% CI)
Brown et al. (n = 396) N/A
(n = 2)
0.634 (0.584–0.681)
(n = 34)
N/A
(n = 4)
N/A
(n = 2)
Fortescue et al. (n = 991) 0.755 (0.727–0.781)
(n = 26)
0.715 (0.686–0.743)
(n = 219)
0.751 (0.723–0.778)
(n = 47)
0.755 (0.727–0.781)
(n = 26)
Mehta et al. (n = 1038) 0.776 (0.750–0.801)
(n = 37)
0.716 (0.688–0.744)
(n = 240)
0.746 (0.718–0.772)
(n = 61)
0.783 (0.756–0.807)
(n = 38)
Thakar et al. (n = 824) 0.837 (0.810–0.862)
(n = 33)
0.731 (0.699–0.761)
(n = 215)
0.811 (0.783–0.838)
(n = 52)
0.842 (0.816–0.867)
(n = 34)
Wijeysundera et al. (n = 824) 0.706 (0.674–0.737)a
(n = 33)
0.657 (0.623–0.689)a
(n = 215)
0.702 (0.669–0.733)a
(n = 52)
0.698 (0.665–0.729)a
(n = 34)
Continuous variables are presented as mean (SD) or median (IQ range) where appropriate, and categorical variables are presented as number (%).
AKI: acute kidney injury; KDIGO-AKI stages 1–3: according to Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group [23];
AUC: area under curve; CI: confidence interval.
aP < 0.05 compared with Thakar et al. in the DeLong test.
Figure 2: Acute kidney injury-dialysis (AKI-D) incidence of the individual (A) and
grouped (B) score values in Thakar et al. and our patient cohort (calibration plots).
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The incidence of AKI-D in our study was 3.5%, which is higher
than in the original prediction models that we validated, where the
incidence of AKI-D ranged from 1.1 to 2.7% [5–9]. In other studies
that validated these original prediction models, incidence of AKI-D
ranged from 1.9 to 10.9% [15–20]. The incidence of AKI according
to KDIGO criteria in our study was 17.3% for stage 1, 2.1% for stage
2 and 3.6% for stage 3. Machado et al. [3] found similar incidences
for stages 2 and 3 (4 and 3%, respectively), whereas the incidence of
KDIGO-AKI stage 1 in their study was higher (35%). There could be
several reasons for the inequality in AKI-D incidences between
studies. The most important seems to be variable criteria for the ini-
tiation of dialysis, prone to subjective decisions of attending phys-
ician. Also, not strictly defined time period for the development of
AKI, could lead to higher incidence if longer time period is used.
This again emphasizes the need for more objective and uniform cri-
teria for the AKI and also for the postoperative period tested, both
embedded in KDIGO-AKI criteria.
We choose to investigate only models with preoperative predic-
tors of AKI, because we find that possible preventive measures
should start preoperatively, as early as possible. Predictive scores
that use intra- or postoperative variables could delay applying
those measures to the time where AKI has already started.
Thereby, we do not want to diminish the significance of the intra-
and postoperative factors. As potential predictors, we evaluated
only the factors that were found to be significant in original studies
(Supplementary Table 1) [5–9]. In our study, we found higher age,
presence of AF, NYHA III or IV class CHF, prior cardiac surgery,
higher serum creatinine and endocarditis was independently asso-
ciated with AKI-D in multivariable analysis (Table 3). There are dif-
ferences found in predictors of AKI-D compared with the studies
that we evaluated [5–9]. Other validation studies also found such
differences compared with original studies [15–20]. The main
reason for this is the difference in patient characteristics, which
was found in validation studies and in our study too, compared
with the original studies. Also, as mentioned, some predictors,
such as CHF, cardiogenic shock, COPD and emergent status of the
surgery, could be interpreted subjectively by the investigators.
We also explored potential predictors for the KDIGO-AKI. To
our knowledge, this was the first study that used this definition of
AKI to evaluate only preoperative predictors. For the KDIGO-AKI
stage 3, the predictors were similar as for AKI-D, which is to be
expected considering that the definition of KDIGO-AKI stage 3
also includes the initiation of dialysis. In addition to those predic-
tors, higher BMI, female gender, COPD and the use of CPB were
associated with the development of less severe stages of KDIGO-AKI
(Table 3).
Evaluation of five most widely used prediction models of
CS-AKI then followed, where we applied both definitions of AKI.
Models were applicable to selected subgroups of patients (Fig. 1)
according to inclusion and exclusion criteria of the original studies
(Supplementary Table 1) [5–9]. The models of Fortescue et al. [5],
Mehta et al. [7], Thakar et al. [6] and Wijeysundera et al. [8] discrimi-
nated well in the prediction of AKI-D, with AUC ranging from
0.706 (0.674–0.737) to 0.837 (0.810–0.862) (Table 4), whereas for
the model of Brown et al. [9], reliable calculation of AUC was not
possible due to a small number of AKI-D events. Other validation
studies found variable discrimination parameters of the original
studies.
In most of the validation studies, the model of Thakar et al. [6]
showed the best discrimination as in our study too, with AUC
ranging from 0.662 (0.646–0.678) to 0.93 (0.91–0.94) [8, 16, 18–20].
Comparison of the tested models in our population cohort showed
that this difference was statistically significant compared with the
model of Wijeysundera et al. [8]. Direct comparison of different
models in the same population cohort was also done by Kiers
et al. [20], and the difference was statistically significant between
the models of Thakar et al. [6] and Mehta et al. [7].
Then, we tested the calibration of the model with the highest
AUC (Thakar et al. [6]) by calibration-in-large plots (Fig. 2 and
Supplementary Table 6). Calibration in our subgroup of patients
was poor and the model underestimated the risk for AKI-D,
except for the lower risk categories. Similar findings of poor cali-
bration of the original models were reported also by Candela-
Toha et al. [16] and Heise et al. [ 18]. The main reason for this
poor calibration is the difference in the demographic and clinical
characteristics of our patients compared with the original study
cohort (Supplementary Table 5). Among other differences, our
patients in the subgroup for this analysis were all Caucasians, of
younger age, had lower serum creatinine and also differed in the
type of surgery performed compared with the Thakar et al.
cohort [6]. There are also possible differences in the thresholds
for the initiation of dialysis.
Five available prediction models were then evaluated in the
prediction of KDIGO-AKI. Four models discriminated reasonably,
well with the model of Thakar et al. [6], showing again the highest
predictive value in all stages of KDIGO-AKI (Table 4). The differ-
ence was statistically significant compared with the model of
Wijeysundera et al. [8] at all stages of KDIGO-AKI. The model of
Brown et al. [9] was only validated in the prediction of KDIGO-AKI
stage 1 and higher with the lowest discrimination found. To our
knowledge, this is the first study to evaluate this prediction models
regarding KDIGO-AKI stages. Kiers et al. [20] evaluated these
models in the prediction of CS-AKI according to earlier RIFLE cri-
teria. We found that our multivariable analysis predictors of
CS-AKI showed higher AUC for all outcomes tested in comparison
with tested models. This finding supports the need for local re-
evaluation of widely used prediction models and also for imple-
menting possible corrections of those models with respect to
local population cohorts.
The strength of this study is the inclusion and evaluation of all
available models of CS-AKI that include only preoperative factors
in the prediction of not only AKI-D, but also newly more uniform-
ly defined AKI by KDIGO criteria.
There are also some limitations to our study. First, our study was
retrospective and therefore dependent on medical records and
history, so ascertainment error, recall, informative censoring and
lead-time biases cannot be avoided. The number of patients ana-
lysed was relatively small compared with that of original studies,
with the consecutive lower statistical power of our study. The dif-
ferences in patient populations compared with original studies
could have influenced the outcomes. In the analysis of KDIGO-AKI
stages, the urine output was not always documented, although
measured, and therefore could not be used as a criterion for
KDIGO-AKI. When evaluating differently defined outcomes against
those in original studies (KDIGO-AKI versus AKI-D), predictive
models may perform differently compared with the original setting.
CONCLUSIONS
Our study identified several independent risk factors for the devel-
opment of cardiac surgery-associated AKI, defined as AKI-D and
KDIGO-AKI stages. Evaluation of well-known prediction models
showed that the model of Thakar et al. [6] had the highest predictive
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value in the discrimination of patients with risk for AKI-D as well as
for all KDIGO-AKI stages. Although it showed miscalibration, it could
still be used to detect patients who are at high risk of AKI-D and also
for less severe stages of CS-AKI. More studies are, however, needed
to develop and/or validate scores to predict non-dialysis CS-AKI.
SUPPLEMENTARY MATERIAL
Supplementary material is available at ICVTS online.
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